

1 G-quadruplex structures mark human regulatory chromatin

2 Robert Hänsel-Hertsch¹, Dario Beraldi¹, Stefanie V. Lensing¹, Giovanni Marsico¹, Katherine
3 Zyner¹, Aled Parry¹, Marco Di Antonio², Jeremy Pike¹, Hiroshi Kimura⁴, Masashi Narita¹, David
4 Tannahill¹ & Shankar Balasubramanian^{1,2,3}

5 1. Cancer Research UK, Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom.

6 2. Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.

7 3. School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.

8 4. Cell Biology Unit, Institute of Innovative Research, Tokyo Institute of Technology,
9 Yokohama, Japan

10 Correspondence and requests for materials should be addressed to S.B. (sb10031@cam.ac.uk).

11

12 G-quadruplex (G4) structural motifs have been linked to transcription^{1,2}, replication³ and genome
13 instability^{4,5} and are implicated in cancer and other diseases⁶⁻⁸. However, it is crucial to
14 demonstrate the *bona fide* formation of G4 structures within an endogenous chromatin context^{9,10}.
15 Herein, we address this via the development of G4 ChIP-seq, an antibody-based G4 chromatin
16 immunoprecipitation and high-throughput sequencing approach. We find that ~10,000 G4s are
17 predominantly present in human regulatory, nucleosome-depleted chromatin. G4s were enriched
18 in the promoters and 5'UTR regions of highly transcribed genes, particularly in genes related to
19 cancer and in somatic copy number amplifications, such as *MYC*. Strikingly, *de novo* and
20 enhanced G4 formation is associated with increased transcriptional activity as revealed by small
21 molecule-induced chromatin relaxation and in immortalized versus normal cellular states. Our
22 findings show for the first time that regulatory, nucleosome-depleted chromatin and elevated
23 transcription shape the endogenous human G4 DNA landscape.

24

25 Regulatory regions in chromatin are characterized by nucleosome depletion to allow access of
26 proteins directing gene transcription, replication and epigenetic plasticity¹¹. These accessible
27 regions are quantitative indicators of cellular fate, origin and identity,¹² yet the underlying DNA
28 structural features remain largely uncharacterized. G4 DNA structures have recently been
29 visualized in human cells^{13,14} and directly mapped in purified genomic DNA¹⁵. Employing G4-
30 promoting conditions, ~700,000 G4-induced polymerase-stalling sequences have been observed
31 in the human genome *in vitro* using purified single-stranded DNA as a template for G4-seq, a
32 high-throughput sequencing method for the discovery of structural features in DNA¹⁶. G4s have
33 been computationally predicted to form in replication origins^{17,18} and nucleosome-depleted
34 regions¹⁹. Endogenous proteins, such as human ATRX²⁰ and XPB/XPD¹ and yeast Pif-1²¹ and
35 Rif-1²² have been mapped by ChIP-seq to G-rich genomic sequences predicted to adopt G4s *in*

36 *vivo*, however, direct capture of G4 structure formation at high-resolution within a chromatin
37 context is missing.

38 We set out to elucidate the relationship between G4 structure, chromatin and transcription in
39 human cells. To achieve this, we developed a G4 ChIP-seq protocol employing an engineered G4
40 structure-specific antibody (BG4)¹³ to map the genome-wide location of G4s in the chromatin of
41 the spontaneously immortalized, non-oncogenic, human epidermal keratinocyte HaCaT cell line²³
42 (Fig. 1, Supplementary Fig. 1). We mapped nucleosome-depleted regions, using Formaldehyde
43 Assisted Isolation of Regulatory Elements and sequencing (FAIRE-seq)²⁴ and Assay for
44 Transposase Accessible Chromatin and sequencing (ATAC-seq)²⁵ (Supplementary Fig. 1) and
45 determined transcriptional output by RNA-seq. Overall in HaCaT chromatin 10,560 high-
46 confidence G4 ChIP-seq peaks were identified with 87 % conforming to an *in vitro* observed G4
47 structural motif (Fig. 1, Supplementary Fig. 2, see method section, ‘*G4 motif and enrichment*
48 *analysis*’)¹⁶. Analysis of G4 motifs revealed that 21 % of all G4 ChIP-seq peaks contain G4
49 motifs, with loop sizes of 1–7 (canonical G4s) (Supplementary Fig. 2)²⁶. Canonical G4s were
50 enriched more in G4 ChIP-seq peaks than other G4 motifs (Supplementary Fig. 2), e.g. with
51 longer loops²⁷ or bulges in G-tracts²⁸. We also validated the G4-structure specific enrichment
52 observed in the HaCaT G4 ChIP-seq peaks in control experiments by G4 ChIP-qPCR, such as
53 pre-incubation of BG4 with a G4-forming or single-stranded DNA sequence prior to G4 ChIP
54 (Supplementary Fig. 3), and by bioinformatic analysis of recurrent MEME-derived motifs and
55 their density in G4 ChIP-seq regions (Supplementary Fig. 2). Strikingly, most (98 %) G4 ChIP-
56 seq peaks overlapped with regions as defined by the union of FAIRE- and ATAC-seq regions
57 (Fig. 1b). We considered the possibility that BG4 might simply target the most accessible open
58 chromatin regions, rather than true G4 sites. To rule out that BG4 enriches the most abundant
59 accessible chromatin sites, regardless of G4 presence, we overlapped the high-confidence G4
60 ChIP-seq peak set (10,560) with the 10,560 most accessible FAIRE sites. FAIRE accessibility
61 was ranked according to q-value for peak enrichment assigned by the MACS2 peak caller. We
62 found that ~44 % of the G4 ChIP-seq peaks did not overlap with these highly accessible FAIRE
63 sites but are actually found in relatively less accessible FAIRE sites than the 10,560 most
64 accessible FAIRE sites. This suggests that chromatin accessibility alone is not sufficient for BG4
65 binding. We further validated the presence of G4 structures in nucleosome-depleted chromatin
66 using immunofluorescence microscopy colocalization for BG4 and another G4 antibody (1H6)¹⁴,
67 with eu- and heterochromatin markers in HaCaT cells. We found that both antibodies
68 significantly colocalized with transcriptionally active euchromatin (H3K4me3 and/or RNA Pol2),

69 while they showed no significant colocalization with heterochromatin (H3K9me3)
70 (Supplementary Fig. 4). Collectively, these results demonstrate that G4 formation in human cells
71 is predominantly restricted to regulatory nucleosome-depleted regions in euchromatin.

72 Overall, HaCaT G4 ChIP-seq peaks represent about 1 % of all sequences detected by G4-seq¹⁶
73 (hereon referred to as **O**bserved **Q**uadruplex sequences) (Supplementary Fig. 5). However, of all
74 OQs that map to nucleosome-depleted regions in HaCaT cells, only a subset (26 %) overlapped
75 with G4 ChIP-seq peaks (Supplementary Fig. 5). Importantly, the remaining 74 % OQs not
76 detected by BG4 in nucleosome-depleted regions showed a comparable representation of G4
77 motifs (sequence and structure) to the positive G4 ChIP subset (26 %) (Supplementary Fig. 5).
78 This suggests that additional genomic features/events, besides nucleosome-depletion, are likely to
79 be important for G4s to form stably in chromatin. While the G4 ChIP-seq peaks are considerably
80 enriched in promoter and 5'UTR regions, i.e. found more often than expected by random chance,
81 they are mostly located outside of these regions (Fig. 1c). This raises the possibility that the
82 transcriptional state of a gene might affect G4 formation in nucleosome-depleted regions. Indeed,
83 we observed genes (4,522) that display a G4 ChIP-seq peak in their promoter have on average
84 significantly ($p = < 0.0001$) higher transcriptional levels than genes (4,345) lacking a promoter
85 G4 ChIP-seq peak, yet are still found nucleosome-depleted and contain an OQ (Fig. 1d). Since
86 regulatory proteins shape open chromatin, we anticipated that published ChIP-seq for XPB/XPD¹
87 or SP1²⁹ that unwind or bind G4s *in vitro* or Δ NP63 a master regulator of keratinocyte
88 transcription³⁰, would be enriched in the G4 ChIP-seq data. Indeed, a notable enrichment of all,
89 XPB/XPD (60-fold), SP1 (330-fold) and Δ NP63 (72-fold) high-confidence peaks were observed
90 in the HaCaT G4 ChIP-seq data, suggesting that these might directly interact with endogenous
91 G4s (Fig. 1b). In contrast and as anticipated, the H3K9me3 and H3K27me3 ChIP-seq peaks
92 showed no correlation with the G4 ChIP-seq sites (Fig. 1b). Taken together, these results suggest
93 that the chromatin context predominantly restricts G4 formation to regulatory nucleosome-
94 depleted regions associated with genes showing elevated transcription. This is consistent with
95 transcriptional up-regulation of predicted G4-forming genes observed in G4 helicase-deficient
96 (i.e. WRN, BLM) human cells³¹ and binding sites of G4 helicases XPB, XPD and the yeast PIF-1
97 homolog, Pfh1, in transcriptionally active chromatin^{1,32}. Fig. 1a shows example profiles for G4
98 ChIP-, ATAC- and FAIRE-seq aligned with peak profiles that mark OQs for the *SRC* and *MYC*
99 oncogenes, that have previously been suggested to be regulated by G4s^{2,10}. Here, we directly
100 confirm the presence of G4 structures in the nuclease hypersensitivity element of the oncogenes
101 *MYC*, and in the upstream element and gene body of *SRC* (Fig. 1a). Recently, we reported an

102 enrichment of OQs at cancer-related genes and somatic copy number alterations (SCNAs)¹⁶, we
103 now extend these findings to show endogenous G4 (i.e. G4 ChIP) enrichment in cancer-related
104 genes, such as *MYC*, *TP53*, *JUN*, *HOXA9*, *FOXA1*, *RAC1* (Supplementary Fig. 6, Supplementary
105 Table 1) and SCNAs (Supplementary Fig. 7, Supplementary Table 2). Among all cancer-related
106 SCNA amplifications and oncogenes, *MYC* shows the highest G4 ChIP density, supporting an
107 already suggested role³³ for G4 structures in cancer progression (Supplementary Fig. 6, 7).

108 We reasoned that if G4 structures are coupled to nucleosome-depletion and their transcriptional
109 status, then changing the chromatin landscape would cause a concomitant shift in the G4 profile.
110 We induced chromatin relaxation of HaCaT cells using the histone deacetylase (HDAC) inhibitor
111 Entinostat³⁴ to stabilize transcriptionally active chromatin through promoter-specific histone
112 H3K27 acetylation³⁵. HaCaT cells treated with 2 μ M Entinostat for 48h³⁵ were analyzed by G4
113 ChIP-, ATAC-, and RNA-seq (Fig. 2, Supplementary Fig. 8). Genome-wide changes in G4 ChIP-
114 seq peaks, open chromatin and mRNA levels were quantified bioinformatically by Differential
115 Binding Analysis (DBA)³⁶ (Fig. 2a, b, Supplementary Fig. 8). HDAC inhibition resulted in the
116 appearance of 4,117 new, or more intense G4 ChIP-seq sites and 7,970 open chromatin regions
117 (Fig. 2a, b). The emergent 4,117 G4 ChIP-seq sites are located in new or pre-existing
118 nucleosome-depleted regions, e.g. *SIGIRR*, *GRIN1* and a non-coding region (Fig. 2a, c), however,
119 importantly none of these sites were found in nucleosome-depleted regions in closed chromatin
120 after Entinostat treatment (Fig. 2a, c). Next, we explored the relationship between G4s identified
121 in promoters of nucleosome-depleted regions and their transcriptional status of associated genes
122 by comparing RNA-seq data to G4 ChIP-seq peaks between untreated and Entinostat treated
123 cells. Consistent with the outcome in untreated cells (Fig. 1d), we observed that genes with OQs
124 in promoters that overlap with both a G4 ChIP-seq peak and an ATAC-seq peak have on average
125 a significantly higher transcriptional output ($P < 0.0001$) than promoters without a G4 ChIP-seq
126 peak in Entinostat treated HaCaTs (Supplementary Fig. 8). Importantly, for promoters that
127 showed a new or larger G4 ChIP-seq peak, but no significant change in their open chromatin state
128 after Entinostat treatment, transcriptional output also increased in comparison to their untreated
129 state ($P < 0.0001$) (Fig. 2d). This indicates that there is a positive and dynamic relationship
130 between G4 structure and transcriptional activity independent of the degree of chromatin
131 accessibility (Fig. 2d), and further suggests that G4s epigenetically mark the genome, whereby
132 four-stranded structure formation rather than the underlying sequence *per se* is directly linked to
133 elevated transcription.

134 We next investigated how an altered cellular state results in chromatin, G4 and transcriptional
135 changes by comparing normal human epidermal keratinocytes (NHEKs) and their spontaneously
136 immortalized counterpart, the HaCaT cell line. Using G4 ChIP-seq, ATAC/FAIRE-seq (Fig. 3,
137 Supplementary Fig. 9), we found that while NHEKs exhibit 85,668 more nucleosome-depleted
138 regions than HaCaT cells (Supplementary Fig. 9), there are less ChIP-seq peaks in NHEKs as
139 compared to HaCaTs (1,496 vs. 10,560) (Fig. 3b). The G4 ChIP-seq peaks identified in HaCaT
140 cells (8,478, 80%), but absent from NHEKs, were found located entirely within nucleosome-
141 depleted regions common to both cell lines (Fig. 3a), suggesting that additional mechanism(s),
142 beyond having a nucleosome-depleted environment, control G4 formation in NHEKs relative to
143 HaCaTs. Indeed, genes comprising promoter G4 ChIP-seq peaks with OQs that were present
144 exclusively in HaCaTs showed an overall increase in transcription as compared to genes
145 containing promoter G4 ChIP-seq peaks common to both cellular states (Fig. 3c, Supplementary
146 Fig. 9).

147 It is noteworthy that we identified G4s in many cancer genes, for example *MYC*, *PTEN* and
148 *KRAS*, in immortalized HaCaT cells but not in NHEKs (Fig. 3a), suggesting a link between
149 increased proliferative capacity/immortalization²³ and G4s. We determined whether the increased
150 presence of G4s in HaCaT cells versus NHEKs was also reflected in the G4 foci observed in
151 nuclei visualized by BG4 immunofluorescence microscopy¹³. Consistent with our G4 ChIP-seq
152 data, we found that HaCaT cells showed ~4-fold (20 ± 8 vs. 5 ± 2) more G4 foci than NHEKs
153 (Fig. 3d, Supplementary Fig. 8). We have previously shown that the G4-selective small molecule
154 pyridostatin (PDS) binds G4 structures, inducing a transcription- and replication-dependent DNA
155 damage response, thus inhibiting cell growth^{10,37}. We therefore investigated PDS sensitivity of
156 HaCaTs vs. NHEKs. We found that HaCaTs are ~7-times more sensitive to growth inhibition by
157 PDS as determined by GI₅₀ (0.9 ± 0.3 vs. 6.5 ± 0.4 μ M) values than NHEKs and is consistent
158 with an increased number of G4s in HaCaTs (Fig. 3e). This increased abundance of G4s mirrors
159 our previous observation that G4 structures can be more prevalent in cancer as compared to
160 matched normal tissue³⁸ and suggests a potential rationale for selective cancer intervention by G4
161 targeting.

162 Here, we provide the first high-resolution genome-wide map of G4 structures in human
163 chromatin. The number of G4 ChIP-seq sites (~10,000) is substantially lower than predicted by
164 computation²⁶ or observed by G4-seq¹⁶, and likely reflects the generally suppressive role of
165 heterochromatin for G4 formation in human cells (e.g. nucleosome density), which may be
166 different in other species³⁹. More G4 ChIP-seq peaks are observed than BG4 IF foci¹³ and is

167 explained by the higher sensitivity and resolution of the ChIP-seq method. We conclude that G4s
168 show hallmarks of dynamic epigenetic features in chromatin primarily found in regulatory,
169 nucleosome-depleted regions and correlated with genes showing elevated transcription (Fig. 4).
170 While small-molecule G4 stabilization can promote a DNA damage response^{10,40} and can cause
171 transcriptional repression², our study suggests that endogenous G4 structures in promoters are
172 ordinarily linked to elevated transcriptional activity. We have also discovered that the
173 endogenous G4 landscape is dynamically altered depending on chromatin relaxation or cell
174 status; and that G4s are particularly enriched in cancer-related genes and regions predisposed to
175 amplification in cancer. Our study further illustrates the potential of the G4 structural motif as a
176 *bona fide* target for disease, diagnosis and intervention.

177 **URLs** Reprints and permissions information are available at www.nature.com/reprints. A sample
178 sheet describing the detailed experimental design is available at [https://github.com/sblab-](https://github.com/sblab-bioinformatics/dna-secondary-struct-chrom-lands)
179 [bioinformatics/dna-secondary-struct-chrom-lands](https://github.com/sblab-bioinformatics/dna-secondary-struct-chrom-lands). Details of data analysis have been deposited at
180 <https://github.com/sblab-bioinformatics/dna-secondary-struct-chrom-lands>. Lists of oncogenes
181 and tumor-suppressor genes were obtained respectively from the COSMIC database
182 (<http://cancer.sanger.ac.uk/census>).⁴¹ and tumor suppressor gene database
183 (<http://bioinfo.mc.vanderbilt.edu/TSGene/>)⁴². Peak correlations were performed using the bedtool
184 package (bedtools.readthedocs.org).

185 **Accession codes** The data reported in this paper are available at the NCBI's GEO repository,
186 accession number GSE76688.

187 **Acknowledgements** The authors would like to thank the staff in the Genomic and Light
188 Microscopy and Biorepository core facilities at Cancer Research UK Cambridge Institute. We are
189 grateful to the European Molecular Biology Organization for funding R.H.H. with the EMBO
190 Long-Term Fellowship. We acknowledge support from University of Cambridge and Cancer
191 Research UK program. The Balasubramanian and Narita laboratories are supported by core
192 funding from Cancer Research UK (C14303/A17197).

193 **Author Contributions** R.H.H. developed the G4 ChIP-seq method with help from S.L.. R.H.H.
194 carried out all experiments except for the immunofluorescence microscopy and growth inhibition
195 experimental work and analysis. K.Z., A.P. and M.D.A. carried out immunofluorescence
196 microscopy experiments. M.D.A. performed growth inhibition experiments. R.H.H., D.B. and
197 G.M. designed, implemented and performed the bioinformatic analysis. R.H.H., D.B., S.L., D.T.
198 and S.B. designed epigenome experiments. R.H.H., K.Z., A.P., M.D.A. and M.N. designed

199 immunofluorescence experiments. J.P. analyzed and quantified colocalization
200 immunofluorescence microscopy experiments. H.K. provided the antibodies α -H3K9me3 (Clone
201 CMA304), α -H3K9me3 (clone CMA318) and α -RNA polymerase II carboxy terminal-domain
202 (clone CMA601). All authors interpreted the results. R.H.H. wrote the manuscript with support
203 and contributions from all authors.

204

205 **References**

- 206 1 Gray, L. T., Vallur, A. C., Eddy, J. & Maizels, N. G quadruplexes are genomewide
207 targets of transcriptional helicases XPB and XPD. *Nat Chem Biol* **10**, 313-318 (2014).
- 208 2 Siddiqui-Jain, A., Grand, C. L., Bearss, D. J. & Hurley, L. H. Direct evidence for a G-
209 quadruplex in a promoter region and its targeting with a small molecule to repress
210 c-MYC transcription. *Proc Natl Acad Sci U S A* **99**, 11593-11598 (2002).
- 211 3 Bochman, M. L., Paeschke, K. & Zakian, V. A. DNA secondary structures: stability and
212 function of G-quadruplex structures. *Nat Rev Genet* **13**, 770-780 (2012).
- 213 4 Ribeyre, C. *et al.* The yeast Pif1 helicase prevents genomic instability caused by G-
214 quadruplex-forming CEB1 sequences in vivo. *PLoS Genet* **5**, e1000475 (2009).
- 215 5 Cheung, I., Schertzer, M., Rose, A. & Lansdorp, P. M. Disruption of dog-1 in
216 *Caenorhabditis elegans* triggers deletions upstream of guanine-rich DNA. *Nat Genet*
217 **31**, 405-409 (2002).
- 218 6 Haeusler, A. R. *et al.* C9orf72 nucleotide repeat structures initiate molecular
219 cascades of disease. *Nature* **507**, 195-200 (2014).
- 220 7 Maizels, N. G4-associated human diseases. *EMBO Rep* **16**, 910-922 (2015).
- 221 8 Wolfe, A. L. *et al.* RNA G-quadruplexes cause eIF4A-dependent oncogene translation
222 in cancer. *Nature* **513**, 65-70 (2014).
- 223 9 Rodriguez, R. & Miller, K. M. Unravelling the genomic targets of small molecules
224 using high-throughput sequencing. *Nat Rev Genet* **15**, 783-796 (2014).
- 225 10 Rodriguez, R. *et al.* Small-molecule-induced DNA damage identifies alternative DNA
226 structures in human genes. *Nat Chem Biol* **8**, 301-310 (2012).
- 227 11 Thurman, R. E. *et al.* The accessible chromatin landscape of the human genome.
228 *Nature* **489**, 75-82 (2012).
- 229 12 Stergachis, A. B. *et al.* Developmental fate and cellular maturity encoded in human
230 regulatory DNA landscapes. *Cell* **154**, 888-903 (2013).
- 231 13 Biffi, G., Tannahill, D., McCafferty, J. & Balasubramanian, S. Quantitative visualization
232 of DNA G-quadruplex structures in human cells. *Nat Chem* **5**, 182-186 (2013).
- 233 14 Henderson, A. *et al.* Detection of G-quadruplex DNA in mammalian cells. *Nucleic*
234 *Acids Res* **42**, 860-869 (2014).
- 235 15 Lam, E. Y., Beraldi, D., Tannahill, D. & Balasubramanian, S. G-quadruplex structures
236 are stable and detectable in human genomic DNA. *Nat Commun* **4**, 1796 (2013).
- 237 16 Chambers, V. S. *et al.* High-throughput sequencing of DNA G-quadruplex structures
238 in the human genome. *Nat Biotechnol* **33**, 877-881 (2015).
- 239 17 Cayrou, C. *et al.* The chromatin environment shapes DNA replication origin
240 organization and defines origin classes. *Genome Res* **25**, 1873-1885 (2015).
- 241 18 Foulk, M. S., Urban, J. M., Casella, C. & Gerbi, S. A. Characterizing and controlling
242 intrinsic biases of lambda exonuclease in nascent strand sequencing reveals phasing

243 between nucleosomes and G-quadruplex motifs around a subset of human
244 replication origins. *Genome Res* **25**, 725-735 (2015).

245 19 Hershman, S. G. *et al.* Genomic distribution and functional analyses of potential G-
246 quadruplex-forming sequences in *Saccharomyces cerevisiae*. *Nucleic Acids Res* **36**,
247 144-156 (2008).

248 20 Law, M. J. *et al.* ATR-X syndrome protein targets tandem repeats and influences
249 allele-specific expression in a size-dependent manner. *Cell* **143**, 367-378 (2010).

250 21 Paeschke, K., Capra, J. A. & Zakian, V. A. DNA replication through G-quadruplex
251 motifs is promoted by the *Saccharomyces cerevisiae* Pif1 DNA helicase. *Cell* **145**,
252 678-691 (2011).

253 22 Kanoh, Y. *et al.* Rif1 binds to G quadruplexes and suppresses replication over long
254 distances. *Nat Struct Mol Biol* **22**, 889-897 (2015).

255 23 Boukamp, P. *et al.* Normal keratinization in a spontaneously immortalized aneuploid
256 human keratinocyte cell line. *J Cell Biol* **106**, 761-771 (1988).

257 24 Hogan, G. J., Lee, C. K. & Lieb, J. D. Cell cycle-specified fluctuation of nucleosome
258 occupancy at gene promoters. *PLoS Genet* **2**, e158 (2006).

259 25 Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition
260 of native chromatin for fast and sensitive epigenomic profiling of open chromatin,
261 DNA-binding proteins and nucleosome position. *Nat Methods* **10**, 1213-1218 (2013).

262 26 Huppert, J. L. & Balasubramanian, S. Prevalence of quadruplexes in the human
263 genome. *Nucleic Acids Res* **33**, 2908-2916 (2005).

264 27 Guedin, A., Gros, J., Alberti, P. & Mergny, J. L. How long is too long? Effects of loop size
265 on G-quadruplex stability. *Nucleic Acids Res* **38**, 7858-7868 (2010).

266 28 Mukundan, V. T. & Phan, A. T. Bulges in G-quadruplexes: broadening the definition of
267 G-quadruplex-forming sequences. *J Am Chem Soc* **135**, 5017-5028 (2013).

268 29 Raiber, E. A., Kranaster, R., Lam, E., Nikan, M. & Balasubramanian, S. A non-canonical
269 DNA structure is a binding motif for the transcription factor SP1 in vitro. *Nucleic*
270 *Acids Res* **40**, 1499-1508 (2012).

271 30 McDade, S. S. *et al.* Genome-wide analysis of p63 binding sites identifies AP-2 factors
272 as co-regulators of epidermal differentiation. *Nucleic Acids Res* **40**, 7190-7206
273 (2012).

274 31 Johnson, J. E., Cao, K., Ryvkin, P., Wang, L. S. & Johnson, F. B. Altered gene expression
275 in the Werner and Bloom syndromes is associated with sequences having G-
276 quadruplex forming potential. *Nucleic Acids Res* **38**, 1114-1122 (2010).

277 32 Sabouri, N., Capra, J. A. & Zakian, V. A. The essential *Schizosaccharomyces pombe*
278 Pfh1 DNA helicase promotes fork movement past G-quadruplex motifs to prevent
279 DNA damage. *BMC Biol* **12**, 101 (2014).

280 33 Balasubramanian, S., Hurley, L. H. & Neidle, S. Targeting G-quadruplexes in gene
281 promoters: a novel anticancer strategy? *Nat Rev Drug Discov* **10**, 261-275 (2011).


282 34 Saito, A. *et al.* A synthetic inhibitor of histone deacetylase, MS-27-275, with marked
283 in vivo antitumor activity against human tumors. *Proc Natl Acad Sci U S A* **96**, 4592-
284 4597 (1999).

285 35 Tomazou, E. M. *et al.* Epigenome mapping reveals distinct modes of gene regulation
286 and widespread enhancer reprogramming by the oncogenic fusion protein EWS-
287 FLI1. *Cell Rep* **10**, 1082-1095 (2015).

288 36 Ross-Innes, C. S. *et al.* Differential oestrogen receptor binding is associated with
289 clinical outcome in breast cancer. *Nature* **481**, 389-393 (2012).

290 37 Rodriguez, R. *et al.* A novel small molecule that alters shelterin integrity and triggers
291 a DNA-damage response at telomeres. *J Am Chem Soc* **130**, 15758-15759 (2008).

292 38 Biffi, G., Tannahill, D., Miller, J., Howat, W. J. & Balasubramanian, S. Elevated levels of
 293 G-quadruplex formation in human stomach and liver cancer tissues. *PLoS One* **9**,
 294 e102711 (2014).
 295 39 Hoffmann, R. F. *et al.* Guanine quadruplex structures localize to heterochromatin.
 296 *Nucleic Acids Res* **44**, 152-163 (2016).
 297 40 Gomez, D. *et al.* Telomestatin-induced telomere uncapping is modulated by POT1
 298 through G-overhang extension in HT1080 human tumor cells. *J Biol Chem* **281**,
 299 38721-38729 (2006).
 300
 301




302

303 **Figure 1 G4s are prevalent in regulatory chromatin regions.** (a) Example genome browser
 304 screenshots for *SRC* and *MYC*. Tracks are shown for HaCaT G4 ChIP-seq (top, red) and control
 305 input below (red); regulatory chromatin sites by ATAC and FAIRE-seq (tracks 3 and 4, black)
 306 and G4-seq peaks (Pyridostatin derived OQs) (purple, % mismatches in reads aligned) on the

307 reverse (-ss) and forward strand (+ss)¹⁶, respectively (tracks 5 and 6, purple). **(b)** Enrichment and
308 peak overlap of HaCaT G4 ChIP-seq peaks with different ENCODE protein ChIP-seq data sets⁴³;
309 s.d. (N = 3) **(c)** Enrichment of HaCaT G4 ChIP-seq peaks relative to what is expected by
310 randomly shuffling G4 ChIP-seq peaks in OQs and the absolute proportion of G4 ChIP-seq peaks
311 across different genomic features (N = 3, error bars indicate standard deviation). **(d)** Distribution
312 of mRNA levels (displayed in transcripts per million, log10 scale) are shown for promoter
313 associated genes (4,345) that feature an ATAC-seq peak and an OQs signature in comparison to
314 genes (4,522) that exhibit a promoter G4 ChIP peak, ATAC-seq and OQs feature in HaCaTs.
315 **** indicates significance (P<0.0001; unpaired two-tailed T-test).

316




317

318 **Figure 2 Chromatin relaxation increases G4 prevalence in regulatory chromatin regions.**

319 (a) Genomic view of *SIGIRR*, *GRIN1* and a non-coding region (chr8:143,274,210) showing
 320 overlap between new G4 sites and regulatory chromatin in Entinostat-treated cells. The *SKI*
 321 promoter (right) exemplifies a gene not significantly changed in G4 ChIP-seq or nucleosome-
 322 depletion. Top two tracks: untreated HaCaT cells with G4 ChIP-seq/input (red) and ATAC-seq
 323 (black). Middle three tracks: Entinostat-treated HaCaT cells, G4 ChIP-seq/input HDACi (red),
 324 ATAC-seq HDACi (black). Bottom two tracks- OQs (PDS-derived, purple), reverse (-ss) and
 325 forward strand (+ss)¹⁶, respectively. (b) Differential Binding Analysis (DBA) showing significant

326 (FDR <0.05) differences in G4 ChIP-seq and ATAC-seq peaks between Entinostat-treated versus
327 untreated HaCaT cells. Red dots represent peaks where G4 ChIP peaks or nucleosome-depletion
328 (ATAC) is significantly changed in Entinostat-treated compared to untreated HaCaT cells. Red
329 and black arrows indicate increase or decrease of G4 formation and changes in nucleosome-
330 depletion (ATAC-seq), respectively. (c) Peak overlap between increased and decreased G4 ChIP-
331 seq peaks and open chromatin regions, derived from (b). (d) Differential gene expression for
332 promoter-associated genes that i) **do not** contain high-confidence G4 ChIP-seq peaks, but have at
333 least one OQs and ATAC-seq peak unaltered in size between conditions (1,734 promoters), ii) as
334 in i) but contains at least one high-confidence G4 ChIP-seq peak shared between conditions and
335 **do not** contain G4 ChIP-seq peaks significantly increased in size (3,627 promoters), or iii) as in i)
336 but contains G4 ChIP-seq peaks significantly increased in size across conditions (373 promoters).
337 (**** P<0.0001; ordinary one-way ANOVA).

338




339

340 **Figure 3 G4 prevalence is significantly increased in immortalized compared to normal**
 341 **human epidermal keratinocytes.**

342 (a) Genomic view of *PTEN*, *MYC*, *KRAS*, and *TSEN34* in HaCaT and NHEK cells. Tracks are G4
 343 ChIP-seq/input HaCaT (top two, red), ATAC-seq HaCaT (third, black), G4 ChIP-seq/input
 344 NHEK (fourth and fifth, red), ATAC-seq NHEK (sixth, black), OQs (PDS-derived, bottom two
 345 tracks in purple) on the reverse (-ss) and forward strand (+ss)¹⁶, respectively. (b) Overlap of G4
 346 ChIP-seq peaks between HaCaT and NHEK (top), and overlap between G4 ChIP-seq peaks and
 347 shared open chromatin regions (ATAC/FAIRE) (bottom); while both NHEKs and HaCaTs share
 348 G4 and active chromatin regions, NHEKs have ~7-fold less G4s. (c) mRNA levels for promoter-
 349 associated genes featuring i) a G4 ChIP and ATAC-seq peak and an OQ signature (503 genes)

350 common to NHEK and HaCaT cells and ii) a unique G4 ChIP/ATAC/OQs peak signature in
 351 HaCaT cells vs. NHEK (3,617 genes) (**** P<0.0001, unpaired two-tailed T-test). **(d)**
 352 Quantification of immunolocalization (see Supplementary Fig. 9) showing the average number of
 353 BG4 foci per cell increases in HaCaT vs. NHEK cells. 109 and 333 HaCaT nuclei and 186 and
 354 326 NHEK nuclei were analyzed (N = 2). Error bars indicate standard deviation and (****
 355 P<0.0001, unpaired two-tailed T-test). **(e)** Growth inhibition response curves for treatment with
 356 PDS (n = 6, error bars indicate standard deviation). The concentration to give 50 % growth
 357 inhibition (GI₅₀) is indicated for HaCaTs (light grey curve) and NHEKs (dark grey curve).

358



359

360 **Figure 4 G4 DNA formation in chromatin.** G4 DNA formation is highly dependent on
 361 chromatin structure and is frequently found in regulatory nucleosome-depleted regions in
 362 proximity to transcription start sites of genes that undergo elevated transcription.

363

364 **Online Methods**

365 **Cell culture**

366 HaCaT cells were kindly provided by Prof. Fiona Watt and cultured in Dulbecco's Modified
367 Eagle Medium (Thermofisher, DMEM, cat. no. 41965-039) supplemented with 10% fetal bovine
368 serum (FBS) (Thermofisher). U2OS cells were cultured in DMEM (Thermofisher, cat. no. 41966-
369 029) supplemented with 10 % FBS. Normal human epidermal keratinocytes, pooled from
370 multiple donors, were purchased from Thermofisher and cultured in EpiLife medium
371 supplemented with human keratinocyte growth supplement (HKGS) (Thermofisher). Cell line
372 genotypes were certified by the supplier and STR profiling. Cells lines were confirmed
373 mycoplasma-free by RNA-capture ELISA.

374 **G4 ChIP-seq protocol and library preparation**

375 20 million cells were fixed in DMEM (cat no. 41965-039) containing 1 (v/v) % formaldehyde and
376 10 (v/v) % FBS for 15 min at room temperature (RT) followed by quenching with 0.13 M glycine
377 at RT for 10 min. Cells were washed in ice-cold PBS and chromatin isolated and prepared as
378 described by the manufacturer (Chromatrap). Chromatin was sonicated using a Bioruptor Plus
379 (Diagenode). 250 µL of lysed nuclei suspension was sonicated for 25 cycles (30s on/60s off) in
380 1.5 mL TPX sonication tubes (Diagenode) to an average DNA size of 100–500 bp. For chromatin
381 immunoprecipitation (ChIP), 2.5 µL chromatin was blocked at 16 °C for 20 min in 44.5 µL
382 intracellular salt solution (25 mM HEPES pH 7.5, 10.5 mM NaCl, 110 mM KCl, 130 nM CaCl₂,
383 1 mM MgCl₂), containing 1 (w/v) % bovine serum albumin (BSA) (Sigma cat. no. B4287),
384 referred as blocking buffer. Recombinant BG4 and control phage display antibody were
385 expressed as described¹⁴. 200 ng of recombinant BG4 or control phage display antibody were
386 then added and incubated for 1h at 16 °C. Meanwhile, 90 µL beads (SIGMA-ALDRICH Anti-
387 FLAG® M2 Magnetic Beads, cat. no. M8823) were washed 3x with 900 µL blocking buffer and
388 stored on ice in 900 µL blocking buffer (blocked bead solution). Next, 50 µL of blocked bead
389 solution was added to the ChIP reaction (final volume 100 µL) and incubated for 1h at 16 °C with
390 rotation. Beads were magnetically captured and the supernatant discarded and the beads washed
391 three times in 200 µL wash (4 °C) buffer (10mM Tris pH 7.4, 100mM KCl, 0.1 (v/v) % Tween
392 20) with manual agitation. Beads were resuspended in 200 µL wash buffer and incubated on a
393 rotating platform at 37 °C for 10 min. The warm wash procedure was repeated, and beads
394 subjected to a final wash (4 °C) before removing the supernatant and re-suspension in 75 µL of
395 elution buffer, containing 1x TE buffer with 20 µg proteinase K (Thermofisher). Elution was
396 performed at 37 °C for 1h and at 65 °C for additional 2h. Beads were magnetically captured and

397 eluted DNA purified from supernatant using a MinElute kit (Qiagen). For each technical
398 replicate, eluted DNA from four ChIP reactions were combined and the pool subjected to Nextera
399 library preparation as described by the manufacturer (Illumina, cat. no. FC-121-1030). Three
400 independent technical replicates were pulled-down and sequenced for each of the two biological
401 replicates.

402 *G4 ChIP-qPCR*

403 Purified and sonicated DNA (as above) were used to quantify G4 enrichment via qPCR, using
404 Fast SYBR PCR mix (Applied Biosystems, UK), with a BioRad CFX96 quantitative PCR
405 machine. Cycling conditions were 95 °C for 20 s followed by 40 cycles of 3 s at 95°C and 30 s at
406 60°C. We employed primer pairs that target G4 ChIP positive and negative regions
407 (Supplementary Table 3). Relative enrichments were derived with respect to their inputs and
408 normalized to a G4-free enhancer region associated with the *ESR1* gene (Supplementary Table 3).
409 RNase A has been shown to digest G4 RNA^{13,44,45} and G4 DNA/RNA hybrids⁴⁵. For DNase or
410 RNase A treatments, 2 U of TURBOTM DNase (2 U/μL; Thermo Fisher Scientific) or 1μg of
411 RNase A (1 mg/mL, Ambion® Thermo Fisher Scientific) were added to the ChIP blocking buffer
412 chromatin mixture and chromatin digestion, instead of chromatin blocking, was performed at 37
413 °C for 20 min.

414 **Epigenome mapping**

415 FAIRE-seq was performed essentially as described, with minor modifications⁴⁶. Cell lysis was
416 performed using a PRECELLYS® 24 homogeniser and phenol-chloroform extraction was
417 performed using Heavy Phase-Lock Gels (5-PRIME™). Transposase-accessible chromatin using
418 sequencing (ATAC-seq) was performed essentially as described, with minor modifications²⁵.
419 Tagmented DNA samples were amplified (11 PCR cycles) using the Nextera index kit (Illumina,
420 cat. no. FC-121-1011) and open chromatin fractions were size selected (190–300 bp) via 2 (w/v)
421 % agarose E-Gel® SizeSelect™ gels (Themofisher). Total RNA for RNA-seq experiments was
422 extracted using the RNeasy kit (Qiagen, cat. no. 74104), following the manufacturer's
423 instructions. RNA-seq libraries were generated using the Illumina Truseq RNA HT (stranded
424 mRNA) kit (cat. no. RS-122-2103). Overall, 18 G4 ChIP-seq, 18 ATAC-seq, 4 FAIRE-seq and
425 12 RNA-seq libraries were made (Supplementary Fig. 1). All epigenome libraries were sequenced
426 in single-end or paired-end using 75 bp reads and the NextSeq500 platform.

427 **Data analysis**

428 *Mapping, peak calling and peak processing.* Raw fastq reads were trimmed to remove adapter
429 contamination and aligned to the human reference genome version hg19 using cutadapt⁴⁷ and
430 bwa⁴⁸, respectively. Reads with a mapping quality below 10 and marked as positional duplicates
431 were excluded from further analysis. FAIRE-seq, ATAC-seq and G4-ChIP peaks were mapped
432 using MACS2.0⁴⁹. RNA-seq reads were aligned to the human reference genome with tophat2⁵⁰.
433 The Galaxy cistrome platform⁵¹ was employed to process MACS2.0 called peak intervals and to
434 generate high-confidence peak overlaps between biological replicates and area-proportional Venn
435 diagrams. Find Individual Motif Occurrences (FIMO)⁵² analysis was used to quantify the density
436 of the Multiple Em for Motif Elicitation (MEME)⁵³ motifs in the high-confidence G4 ChIP-seq
437 data (HaCaT).

438 *Differential gene expression.* Gene expression levels were quantified as transcripts per million
439 (TPM). Differentially expressed genes between i) HaCaT treated with Entinostat and untreated
440 HaCaT and ii) NHEK vs HaCaT were identified using with the Bioconductor package edgeR
441 (FDR < 0.05; fold change > 1.5)⁵⁴.

442 *G4 transcriptional analysis.* Promoter transcription start site (TSS) coordinates, 1kb (+/-) from
443 TSS, were generated for 22,483 genes using hg19. To reveal absolute gene expression values
444 (TPM, transcripts per million) for promoters with and without a G4 ChIP-seq signature, we
445 divided promoters into two categories: 1) promoters that overlap with at least one high-
446 confidence ATAC-seq peak, at least one OQs (potassium- and PDS-induced) and that overlap
447 with at least one high-confidence G4 ChIP-seq peak, and 2) promoter regions as in 1) that **do not**
448 overlap with the high-confidence G4 ChIP-seq data set of untreated HaCaTs (command intersect,
449 subtract bedtools package).

450 Differential gene expression levels for promoter-associated genes were prepared into 3 subsets as
451 follows: Promoters that 1) **do not** overlap with G4 ChIP-seq peaks, but have at least one OQs and
452 ATAC-seq peak unaltered in size (log2 fold change = -0.6-to-0.6, FDR<0.05 differential binding
453 analysis³⁶) between untreated and Entinostat treated HaCaTs, 2) as in 1) but **do not** overlap with
454 G4 ChIP-seq peaks significantly increased in size for Entinostat treated vs. untreated HaCaTs and
455 overlap with at least one high-confidence G4 ChIP-seq peak shared between untreated and
456 Entinostat treated HaCaTs, or 3) as in 1) but overlap with G4 ChIP-seq peaks significantly
457 increased in size (log2 fold change = >0.6, FDR<0.05 differential binding analysis³⁶) for
458 Entinostat treated vs. untreated HaCaTs (command intersect, subtract bedtools package). ****
459 indicates significance (P<0.0001; ordinary one-way ANOVA).

460 *Epigenome enrichment analysis.* ChIP-seq data from the ENCODE project was retrieved from the
461 NCBI's GEO repository as follows: XPB/XPD (GSE44849); SP1 (ENCSR991ELG;
462 ENCSR000BJX; ENCSR000BHK); H3K9me3 (ENCSR000EYF; ENCSR000ARN;
463 ENCSR000APE); H3K27me3 (ENCSR000EWB; ENCSR000DWU; ENCSR000DUE); CTCF
464 (ENCSR000DWX; ENCSR000EGM; ENCSR000DUG); DeltaNp63 (GSE32061). Overlap
465 between the high confidence HaCaT G4 ChIP-seq peak file and the ENCODE ChIP-seq data sets
466 was tested using the Galaxy cistrome platform⁵¹. Common high confidence ENCODE ChIP-seq
467 peak files across the three different cell lines were calculated, if applicable (see GEO accession
468 numbers). ENCODE ChIP-seq peak files were randomly shuffled (N = 6) across the genome and
469 potential overlaps tested with the G4 ChIP-seq peak file (command shuffleBed of the bedtools
470 package). Enrichments between G4 ChIP-seq and ENCODE ChIP-seq data sets were calculated
471 from the ratio of the direct overlaps with the randomly shuffled overlaps.

472 *G4 ChIP-seq peak annotation and enrichment analysis.* PAVIS⁵⁵ was used to annotate the HaCaT
473 G4 ChIP-seq peaks. The G4 ChIP-seq file was randomly shuffled across a file containing all OQs
474 (potassium and PDS induced) (command shuffleBed of the bedtools package) three independent
475 times and their genomic annotations retrieved via PAVIS, respectively. To calculate enrichments
476 of annotated features, ratios of the annotated G4 ChIP-seq proportions were performed with the
477 proportions of the randomly shuffled features (N = 3).

478 *G4 motif and enrichment analysis.* Sequences within peak regions were analyzed by regular
479 expression matching and assigned to one of the following classes: Loop size 1–3, 4–5 and 6–7:
480 sequences with at least one loop of the respective length; long loop: sequences with a G4 with
481 any loop of length >7 (up to 12 for any loop and 21 for the middle loop); simple bulge: sequences
482 with a G4 with a bulge of 1–7 bases in one G-run or multiple 1-base bulges; 2-tetrads / Complex
483 bulge: sequences with a G4s with two G-bases per G-run or several bulges of 1–5 bases; and
484 other: other G4-types that do not fall into the former categories. Sequences in each peak were
485 assigned to these classes in a hierarchical fashion: for instance, if a sequence matched both the
486 Loop 1–3 and Long loop categories, it was assigned to the former most category, in this case
487 Loop 1–3. The fold enrichment analysis was calculated by comparing actual counts for each class
488 within peak regions to counts of the same peak regions after random reshuffling throughout the
489 genome using the bedtools shuffle command. Results are shown as the average of 10
490 randomizations, and the fold enrichment bar plot displays the ratio of real counts divided by
491 average random counts. For fold enrichment analysis of G4 motifs compared to similar motifs
492 with lower G4 forming potential, we compared respectively: 1) G4 with 4 G-runs of at least 3 Gs

493 each and loop size 1–7 ($G_{3+}L_{1-7}$) compared to a similar motif with 3 G-runs of at least 3 Gs each
494 and loop size 1–7; 2) as 1), but with loop length 1–12 ($G_{3+}L_{1-12}$); 3) as 1), but with G-runs of 2 Gs
495 each, i.e. 2-tetrads (G_2L_{1-7}); 4) canonical G-quadruplex motifs as in 1) ($G_{3+}L_{1-7}$) but with a single
496 bulge of 1–7 bases ($GGH_{1-7}G$, with H=A,T or C) in only one G-run compared to a similar motif
497 with a single G ($H_{1-2}GH_{1-2}$) instead of the bulge motif; 5) same G-quadruplex as in 3) (G_2L_{1-7})
498 compared to a similar motif with one G-run having a single G ($H_{1-2}GH_{1-2}$).

499 *Cancer-related gene analysis.* After remapping to hg19, 555 oncogenes and 1211 tumor
500 suppressors (Supplementary Table 1) were considered. The occurrence of ChIP-seq peaks in each
501 gene was determined and compared to the occurrence within not annotated as cancer genes nor
502 tumor-suppressors. To account for different region size, the peak density was calculated as
503 number of peaks per Megabase (Mb). Peaks occurring within the gene body (i.e., exons + introns)
504 and in proximal promoter regions (i.e., 3000 bases upstream of the transcription start site) were
505 counted separately. P-values for statistical testing were calculated with the non-parametric
506 Wilcoxon rank sum test (implemented as `wilcox.test()` function in the R software).

507 *SCNAs analysis.* Somatic copy number alteration (SCNA) regions associated with cancer
508 ($n=108$), either amplifications ($n=54$) or deletions ($n=54$), (i.e. copy number gains or losses of
509 any length and amplitude), were obtained from the Cancer Genome Atlas Pan-Cancer dataset⁵⁶.
510 ChIP-seq peak abundance in each region was compared to the occurrence of randomly reshuffled
511 peak regions (5 different randomization) in a similar manner to the G4 motif enrichment analysis.
512 To account for different region sizes, peak density was calculated as the number of peaks per
513 megabase (Mb). For visual comparison, we also determined the average genome-wide peak
514 density per Mb ($avg_density = 3.91$), calculated as total number of peaks divided by the effective
515 genome size (2.7×10^9 for *hg19*), multiplied by 1,000,000 bp (Supplementary Table 2).

516 **Immunofluorescence microscopy**

517 BG4 immunostaining and fluorescence microscopy for the HaCaT and NHEK cells were
518 performed as previously described¹³. All secondary or tertiary antibodies were obtained from
519 Thermofisher unless otherwise stated. In brief, cells were fixed with 2 (v/v) % formaldehyde in
520 PBS, permeabilized with 0.1 (v/v) % Triton X100 in PBS, and blocked with 2 (w/v) % Marvel
521 milk (Premier Foods plc) in PBS. After blocking, cells were incubated with BG4 followed by
522 incubation with secondary Rabbit α -FLAG (cat. no. 2368, Cell Signaling Technology) and
523 tertiary goat α -rabbit conjugated with Alexa-594 (cat. no. A11037) at 37 °C in a humid chamber
524 for 1h each. Coverslips were mounted on Prolong Gold/DAPI Antifade (Thermofisher). Digital

525 images were recorded using a DP70 camera (Olympus) on an Axioskop 2 Plus microscope
526 (Zeiss) and analyzed with Fiji⁵⁷. 200–300 nuclei were counted per condition and standard
527 deviations calculated from two biological replicates. Frequency distribution graphs were plotted
528 using GraphPad Prism (GraphPad Software Inc.).

529 For BG4 or 1H6 colocalization studies with H3K4me3, H3K9me3 and RNA polymerase II,
530 HaCaT cells were grown to 50% confluency on # 1.5 glass coverslips. Cells were fixed and
531 permeabilized as above, treated with 50 µg RNase A for 30 min at 37 °C and incubated in
532 blocking buffer for 1h at 37 °C (PBS/ 0.5% normal goat serum, 0.1% Tween 20). For BG4
533 studies, coverslips were incubated with BG4 (10 nM) for 1h at 37 °C, washed three times for 5
534 min with PBST and incubated 37 °C for 1h with rabbit α -FLAG 1:800 (cat. no. 2368, Cell
535 Signalling Technology) and mouse α -H3K9me3 1:200 (Clone CMA304)⁵⁸ or mouse α -H3K9me3
536 1:200 (clone CMA318)⁵⁹ or mouse α -RNA polymerase II carboxy terminal-domain (clone
537 CMA601) 1:200⁶⁰. For 1H6 studies, coverslips were incubated with mouse α -quadruplex DNA
538 (cat. no. Ab00389-1.1, Absolute Antibody) and rabbit α -H3K9me3 1:200 (cat. no. 9751, Cell
539 Signaling Technology) or rabbit α -H3K4 me3 1:500 (cat.no. 07-523, Upstate) for 37 °C for 1h.
540 Subsequently, all coverslips were washed as described and incubated for 30 min at 37 °C with the
541 following Alexa Fluor conjugated antibodies: goat α -rabbit Alexa-488 (cat. no. A-11034) and
542 goat α -mouse Alexa-555 (cat. no. A-21424) for BG4 studies and goat α -mouse Alexa-488 (cat.
543 no. A-11001) and goat α -rabbit Alexa-555 (cat. no. A-21429) for 1H6 studies. DAPI counterstain
544 was included in the final antibody incubation. Following washing, all coverslips were mounted
545 onto Superfrost Plus slides (cat. no. 4951PLUS, Thermofisher) with Vectashield antifade
546 mounting media (cat. No. H-1000, Vector Laboratories Ltd.). Three biological replicates were
547 performed.

548 Confocal z-stack images (15 steps) were acquired using a Leica TCS SP8 microscope with a HC
549 PL APO CS2 1.4NA 100X oil objective (Leica Microsystems), in bidirectional mode, at a scan
550 speed of 400 Hz and sampling rate of 0.06 µm x 0.06 µm x 280 µm. The 405 nm diode laser was
551 used to excite the DAPI channel (at 405 nm) and the white light pulsed laser (SuperK
552 EXTREME, NKT Photonics) was used to excite secondary antibody fluorophores (at 555 nm and
553 488 nm). Fluorescence detection was performed in sequential acquisition mode with hybrid
554 detectors (Leica HyD Photon Counter) at the collection wavelength ranges of 490–535 nm, 565–
555 630 nm and 410–485 nm for Alexa Fluor 488, 555 and DAPI respectively. The pinhole was set to
556 one Airy unit and laser power and gain settings were consistent between replicates. Five to six Z-

557 stacks were obtained per replica representing 60–160 cells each. Representative images were
558 processed using Image J⁶¹/Fiji and Photoshop (Adobe Systems Inc) software and assembled using
559 Adobe Illustrator CS4.

560 Colocalization analysis was performed using an automated workflow in MATLAB (R2015b,
561 Mathworks Inc.) with a link to Image J through MIJ⁶². First, the nuclear region was isolated by
562 blurring the DAPI channel with a 3D Gaussian (radius 0.2 μ m) and Otsu thresholding (stack
563 histogram). Noise reduction of the signal of each colocalization channel was performed using the
564 PureDenoise plugin (ImageJ)⁶³ and isolated by removing background with a rolling ball approach
565 (radius 2 μ m) and Otsu thresholding. The corrected first Mander's overlap coefficient ($M1_{diff}$)
566 corresponds to the difference between the percentage of the G4 antibody (BG4 or 1H6) signal
567 that colocalizes with euchromatin, heterochromatin or gene promoter signal; the expected value
568 for randomly distributed signal was calculated on the isolated signal. Finally, a two-way t-test
569 was performed for each condition across the mean values of $M1_{diff}$ across the three biological
570 replicates⁶⁴, and corrected for multiple hypothesis testing using the Bonferroni correction (n=5).
571 Graphs were created using GraphPad Prism version 6.00.

572 **Small molecule treatment and growth inhibition analysis**

573 HaCaT cells were treated with 2 μ M Entinostat (E5477-5 mg, Cambridge Bioscience) for 48h at
574 30% confluency in 150 mm tissue culture dishes prior to G4 ChIP fixation procedure or ATAC-
575 seq preparation, or in 6-well plates to generate four technical replicates for RNA-seq preparation.
576 The concentration to inhibit by 50% cell growth (GI_{50}) induced by PDS was quantified using the
577 end point Cell Titre Glo assay (Promega). Briefly, 4000 HaCaT and NHEK cells were seeded in a
578 96-well white plates (Nunc) for 18h prior to small molecule treatment. Cells were then treated
579 with PDS doses ranging from 50 to 0.012 μ M for 72h. Cells were then incubated with Cell Titer
580 Glow for 1h at room temperature and luminescence was measured using a PHERAstar FS
581 microplate reader (BMG LabTech). Cell survival curves were plotted and GI_{50} values were
582 calculated using GraphPad Prism (GraphPad Software Inc.). Error bars represent variability
583 within 6 replicates.

584 **Online Methods-only references**

- 585 41 Forbes, S. A. *et al.* COSMIC: exploring the world's knowledge of somatic mutations in
586 human cancer. *Nucleic Acids Res* **43**, D805-811 (2015).
587 42 Zhao, M., Kim, P., Mitra, R., Zhao, J. & Zhao, Z. TSGene 2.0: an updated literature-
588 based knowledgebase for tumor suppressor genes. *Nucleic Acids Res* (2015).

589 43 Consortium, E. P. An integrated encyclopedia of DNA elements in the human
590 genome. *Nature* **489**, 57-74 (2012).

591 44 Biffi, G., Di Antonio, M., Tannahill, D. & Balasubramanian, S. Visualization and
592 selective chemical targeting of RNA G-quadruplex structures in the cytoplasm of
593 human cells. *Nat Chem* **6**, 75-80 (2014).

594 45 Wanrooij, P. H. *et al.* A hybrid G-quadruplex structure formed between RNA and
595 DNA explains the extraordinary stability of the mitochondrial R-loop. *Nucleic Acids*
596 *Res* **40**, 10334-10344 (2012).

597 46 Simon, J. M., Giresi, P. G., Davis, I. J. & Lieb, J. D. Using formaldehyde-assisted
598 isolation of regulatory elements (FAIRE) to isolate active regulatory DNA. *Nat Protoc*
599 **7**, 256-267 (2012).

600 47 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing
601 reads. *EMBnet.journal* **17** (2011).

602 48 Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-
603 MEM. (2013).

604 49 Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137
605 (2008).

606 50 Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of
607 insertions, deletions and gene fusions. *Genome Biol* **14**, R36 (2013).

608 51 Giardine, B. *et al.* Galaxy: a platform for interactive large-scale genome analysis.
609 *Genome Res* **15**, 1451-1455 (2005).

610 52 Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given
611 motif. *Bioinformatics* **27**, 1017-1018 (2011).

612 53 Machanick, P. & Bailey, T. L. MEME-ChIP: motif analysis of large DNA datasets.
613 *Bioinformatics* **27**, 1696-1697 (2011).

614 54 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
615 differential expression analysis of digital gene expression data. *Bioinformatics* **26**,
616 139-140 (2010).

617 55 Huang, W., Loganantharaj, R., Schroeder, B., Fargo, D. & Li, L. PAVIS: a tool for Peak
618 Annotation and Visualization. *Bioinformatics* **29**, 3097-3099 (2013).

619 56 Zack, T. I. *et al.* Pan-cancer patterns of somatic copy number alteration. *Nat Genet*
620 **45**, 1134-1140 (2013).

621 57 Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat*
622 *Methods* **9**, 676-682 (2012).

623 58 Kimura, H., Hayashi-Takanaka, Y., Goto, Y., Takizawa, N. & Nozaki, N. The
624 organization of histone H3 modifications as revealed by a panel of specific
625 monoclonal antibodies. *Cell Struct Funct* **33**, 61-73 (2008).

626 59 Hayashi-Takanaka, Y. *et al.* Tracking epigenetic histone modifications in single cells
627 using Fab-based live endogenous modification labeling. *Nucleic Acids Res* **39**, 6475-
628 6488 (2011).

629 60 Stasevich, T. J. *et al.* Regulation of RNA polymerase II activation by histone
630 acetylation in single living cells. *Nature* **516**, 272-275 (2014).

631 61 Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of
632 image analysis. *Nat Methods* **9**, 671-675 (2012).

633 62 Sage, D., Prodanov, D., Tinevez, J.-Y., Schindelin, J. . in *ImageJ User & Developer*
634 *Conference* 24-26 (2012).

635 63 Luisier, F., Vonesch, C., Blu, T. & Unser, M. Fast Interscale Wavelet Denoising of
636 Poisson-Corrupted Images. *Signal Processing* **90**, 415-427 (2010).

637 64 McDonald, J. H. & Dunn, K. W. Statistical tests for measures of colocalization in
638 biological microscopy. *J Microsc* **252**, 295-302 (2013).

639

640 The authors declare no competing financial interests.